Biology Reference
In-Depth Information
21. Zhou J, Rossi JJ (2011) Cell-speci fi c aptamer-mediated targeted drug delivery. Oligonucleotides
21:1-10
22. Syed MA, Pervaiz S (2010) Advances in aptamers. Oligonucleotides 20:215-224
23. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific
ligands. Nature 346:818-822
24. Robertson DL, Joyce GF (1990) Selection in vitro of an RNA enzyme that specifically cleaves
single-stranded DNA. Nature 344:467-468
25. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA
ligands to bacteriophage T4 DNA polymerase. Science 249:505-510
26. Mayer G (2009) The chemical biology of aptamers. Angew Chem Int Ed Engl 48:2672-2689
27. Famulok M, Hartig JS, Mayer G (2007) Functional aptamers and aptazymes in biotechnology,
diagnostics, and therapy. Chem Rev 107:3715-3743
28. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov
9:537-550
29. Bunka DH, Platonova O, Stockley PG (2010) Development of aptamer therapeutics. Curr
Opin Pharmacol 10:557-562
30. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W (2008) Applications of aptamers in cancer
cell biology. Anal Chim Acta 621:101-108
31. Guo KT, Paul A, Schichor C, Ziemer G, Wendel HP (2008) CELL-SELEX: novel perspectives
of aptamer-based therapeutics. Int J Mol Sci 9:668-678
32. Cerchia L, Giangrande PH, McNamara JO, de Franciscis V (2009) Cell-specific aptamers for
targeted therapies. Methods Mol Biol 535:59-78
33. Hicke BJ et al (2001) Tenascin-C aptamers are generated using tumor cells and purified pro-
tein. J Biol Chem 276:48644-48654
34. Kulbachinskiy AV (2007) Methods for selection of aptamers to protein targets. Biochemistry
(Mosc) 72:1505-1518
35. Berezovski M et al (2005) Nonequilibrium capillary electrophoresis of equilibrium mixtures:
a universal tool for development of aptamers. J Am Chem Soc 127:3165-3171
36. Berezovski M, Musheev M, Drabovich A, Krylov SN (2006) Non-SELEX selection of aptam-
ers. J Am Chem Soc 128:1410-1411
37. Mallikaratchy P, Stahelin RV, Cao Z, Cho W, Tan W (2006) Selection of DNA ligands for
protein kinase C-delta. Chem Commun (Camb)30: 3229-3231
38. Farokhzad OC et al (2005) Microfluidic system for studying the interaction of nanoparticles
and microparticles with cells. Anal Chem 77:5453-5459
39. Xu Y, Phillips JA, Yan J, Li Q, Fan ZH, Tan W (2009) Aptamer-based microfluidic device for
enrichment, sorting, and detection of multiple cancer cells. Anal Chem 81:7436-7442
40. Zhou J et al (2009) Selection, characterization and application of new RNA HIV gp 120 aptam-
ers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res
37(9):3094-3109
41. Li N, Larson T, Nguyen HH, Sokolov KV, Ellington AD (2010) Directed evolution of gold
nanoparticle delivery to cells. Chem Commun (Camb) 46:392-394
42. Chen CH et al (2008) Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci
U S A 105:15908-15913
43. Kraus E, James W, Barclay AN (1998) Cutting edge: novel RNA ligands able to bind CD4
antigen and inhibit CD4+ T lymphocyte function. J Immunol 160:5209-5212
44. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-
stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific mem-
brane antigen. Cancer Res 62:4029-4033
45. Cerchia L, de Franciscis V (2010) Targeting cancer cells with nucleic acid aptamers. Trends
Biotechnol 28:517-525
46. Cerchia L et al (2005) Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor
tyrosine kinase. PLoS Biol 3:e123
47. Pestourie C et al (2006) Comparison of different strategies to select aptamers against a trans-
membrane protein target. Oligonucleotides 16:323-335
Search WWH ::
Custom Search